Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech
On the latest BioCentury This Week podcast, BioCentury’s editors assess the shifting market for biotech IPOs, including the profiles of the three companies that went public on NASDAQ last week, the aftermarket performance of the year's IPO class, and the prospects for more companies to make their own debut in the coming months. BioCentury’s editors also discuss whether the rush to GLP-1s for obesity will mirror the development of PD-1s for cancer and the impact on biopharma of the recent mainstream expansion of AI. This episode of BioCentury This Week was sponsored by Parexel Biotech.
View full story: https://www.biocentury.com/article/653538
00:01 - Sponsor Message: Parexel Biotech
01:30 - IPOs
10:56 - GLP-1 & Obesity
22:18 - AI & Biotech
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Available Results
Generated results are saved to the knowledge database for reuse and search.
Extract Knowledge
Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.